BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $563 from $565 and keeps a Buy rating on the shares. The firm, which expects steady growth for the cystic fibrosis franchise in Q3, remains “bullish” on the strong commercial performance of the CF franchise and multiple shots on goal across the portfolio, the analyst tells investors in a preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strong Market Position and Growth Potential Reinforce Buy Rating
- Vertex Pharmaceuticals announces updates across program for povetacicept
- Vertex Pharmaceuticals price target lowered to $438 from $439 at Morgan Stanley
- Vertex Pharmaceuticals: Strong Growth Potential with Promising Product Launches and Robust Pipeline
- Vertex Pharmaceuticals price target raised to $575 from $550 at Citi